A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk-Reference-Cited by-同舟云学术

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk

Published:2013-10-29 Issue:2 Volume:142 Page:389-398
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Vinayak Shaveta,Schwartz Erich J.,Jensen Kristin,Lipson Jafi,Alli Elizabeth,McPherson Lisa,Fernandez Adrian M.,Sharma Vandana B.,Staton Ashley,Mills Meredith A.,Schackmann Elizabeth A.,Telli Melinda L.,Kardashian Ani,Ford James M.,Kurian Allison W.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-013-2739-z.pdf

Reference47 articles.

1. American Cancer Society: Cancer Facts and Figures (2013) http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013 . Accessed Jan 2013

2. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893–1907. doi: 10.1158/1055-9965.EPI-10-0437

3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388

4. Li Y, Brown PH (2007) Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev 16(3):203–215. doi: 10.1097/CEJ.0b013e328011ed9800008469-200706000-00007

5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741. doi: 10.1001/jama.295.23.joc60074

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statin use as a moderator on the association between metformin and breast cancer risk in women with type 2 diabetes mellitus;Cancer & Metabolism;2024-04-12

2. Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance;Antibiotics;2023-09-20

3. New insights into the therapeutic potentials of statins in cancer;Frontiers in Pharmacology;2023-07-07

4. The role of cholesterol metabolism in tumor therapy, from bench to bed;Frontiers in Pharmacology;2023-04-06

5. Unraveling the actin cytoskeleton in the malignant transformation of cholangiocyte biology;Translational Oncology;2022-12